0001193125-24-136243.txt : 20240510 0001193125-24-136243.hdr.sgml : 20240510 20240510164535 ACCESSION NUMBER: 0001193125-24-136243 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 EFFECTIVENESS DATE: 20240510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001274792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35409 FILM NUMBER: 24935675 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-441-1000 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 25 1 d838859d25.htm FORM 25 Form 25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 001-35409

 

 

Issuer: Merrimack Pharmaceuticals, Inc.

Exchange: Nasdaq Capital Market

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

 

 

One Broadway, 14th Floor

Cambridge, MA 02142

(617) 720-8606

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common stock, par value $0.01 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

☐

17 CFR 240.12d2-2(a)(1)

 

☐

17 CFR 240.12d2-2(a)(2)

 

☐

17 CFR 240.12d2-2(a)(3)

 

☐

17 CFR 240.12d2-2(a)(4)

 

☐

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

 

☒

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

 

1 

Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Pursuant to the requirements of the Securities Exchange Act of 1934, Merrimack Pharmaceuticals, Inc. (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

MERRIMACK PHARMACEUTICALS, INC.

By:   /s/ Gary L. Crocker
Name:   Gary L. Crocker
Title:   President and Chairman of the Board

Date: May 10, 2024